| For: | Poulose JV, Kainickal CT. Immune checkpoint inhibitors in head and neck squamous cell carcinoma: A systematic review of phase-3 clinical trials. World J Clin Oncol 2022; 13(5): 388-411 [PMID: 35662989 DOI: 10.5306/wjco.v13.i5.388] |
|---|---|
| URL: | https://www.wjgnet.com/2218-4333/full/v13/i5/388.htm |
| Number | Citing Articles |
| 1 |
Miguel Caballero-Borrego, Aida Piedra, Óscar Gallego, Antonio López-Pousa, Paola Castillo, Pilar Navarrete, Alba Prat, Juan J. Grau. Walking one hour per day and the derived neutrophil-to-lymphocyte ratio are associated with outcome in palliative second-line immunotherapy for patients with recurrent and/or metastatic squamous cell carcinoma of head and neck. Brazilian Journal of Otorhinolaryngology 2024; 90(6) doi: 10.1016/j.bjorl.2024.101493
|
| 2 |
Lukas A. Brust, Meike Vorschel, Sandrina Körner, Moritz Knebel, Jan Philipp Kühn, Silke Wemmert, Sigrun Smola, Mathias Wagner, Bernhard Schick, Maximilian Linxweiler. Impact of T Cell Exhaustion and Stroma Senescence on Tumor Cell Biology and Clinical Outcome of Head and Neck Squamous Cell Carcinomas. International Journal of Molecular Sciences 2024; 25(24) doi: 10.3390/ijms252413490
|
| 3 |
Gissel Geovanna Bermello-Chacha, Solange Stephanie Bazurto-Escobar, Jefry Alessio Mendoza-Castillo, Lisseth Margarita Zambrano-Cedeño. Calidad de vida en pacientes diagnosticados de cáncer oral: revisión sistemática. Cuaderno de odontología. Revista científica 2026; 5(especial7) doi: 10.62574/zxuyxxa9
|
| 4 |
Svein Erik Moe, Fredrik A. Erland, Siren Fromreide, Stein Lybak, Marianne Brydoy, Harsh N. Dongre, Sophia M. Dhayalan, Daniela-Elena Costea, Olav K. Vintermyr, Hans Jørgen Aarstad. The TP53 Codon 72 Arginine Polymorphism Is Found with Increased TP53 Somatic Mutations in HPV(−) and in an Increased Percentage among HPV(+) Norwegian HNSCC Patients. Biomedicines 2023; 11(7) doi: 10.3390/biomedicines11071838
|
| 5 |
Armin Nejat Dehkordi, Moein Maddahi, Parinaz Vafa, Nasim Ebrahimi, Amir Reza Aref. Salivary biomarkers: a promising approach for predicting immunotherapy response in head and neck cancers. Clinical and Translational Oncology 2024; 27(5) doi: 10.1007/s12094-024-03742-8
|
| 6 |
Brett M. Garabedian, Eleanor E. Bashian, Xiaoshuang Wang, Andrew J. Thompson, James C. Paulson. Targeting Sialidase to PD1 Enhances T cell Function and Tumor Control. ACS Central Science 2025; 11(8) doi: 10.1021/acscentsci.5c00510
|
| 7 |
Martina Raudenská, Maria Bugajová, David Kalfeřt, Jan Plzák, Adam Šubrt, Petra Tesařová, Michal Masařík. The interplay between microbiome and host factors in pathogenesis and therapy of head and neck cancer. Biochimica et Biophysica Acta (BBA) - Reviews on Cancer 2024; 1879(6) doi: 10.1016/j.bbcan.2024.189216
|
| 8 |
Yizhou Yang, Zeman Cai, Kaichun Huang, Mei Li, Xiao Wang, Yinbing Lin, Sijie Chen, Zhining Yang, Zhixiong Lin. A composite score based on immune-related gene prognostic index and m6A risk score of head and neck squamous cell carcinoma. Frontiers in Genetics 2023; 14 doi: 10.3389/fgene.2023.1061569
|
| 9 |
Paulien Van Loocke, Benoit Beuselinck, Jeroen Meulemans, Sandra Nuyts, Robin Willaert, Davide Di Santo, Esther Hauben, Robert Hermans, Abhishek D. Garg, Vincent Vander Poorten, Oliver Bechter, Paul M. Clement. Impact of time-of-day administration of immune checkpoint inhibitors on survival outcomes in patients with recurrent/metastatic head and neck cancer (R/M HNSCC): a retrospective cohort study. Oral Oncology 2025; 171 doi: 10.1016/j.oraloncology.2025.107772
|
| 10 |
Sonja Steen, Karl Semmelmayer, Christa Flechtenmacher, Jürgen Hoffmann, Kolja Freier, Dominik Horn, Jochen Hess, Christian Freudlsperger, Julius Moratin. Dynamic Up-Regulation of PD-L1 in the Progression of Oral Squamous Cell Carcinoma. International Journal of Molecular Sciences 2023; 24(22) doi: 10.3390/ijms242216386
|
| 11 |
Kaviyashri Ramesh, Sudharshini Srinivasan, Sharmila Sakthisivanandhan, Dhanush Periyasamy, Sree Ram Sivakumar, Praveenkumar Ramesh, Karthikeyan Elumalai. Biomarker-guided precision immunotherapy in head and neck cancer: Harnessing toripalimab-tpzi as a PD-1 checkpoint inhibitor. Advances in Biomarker Sciences and Technology 2026; 8 doi: 10.1016/j.abst.2026.01.010
|
| 12 |
Ruey-Long Hong, Chia-Jui Yen, Ming-Yu Lien, Rebecca Cheng, Yu-Wen Su, Han-Nan Lin, Song Ling Poon, Chih-Yen Chien. Betel-nut chewing does not influence PD-L1 expression rates in recurrent/metastatic head and neck squamous cell carcinoma (HNSCC): A prospective biomarker prevalence study. Oral Oncology 2024; 152 doi: 10.1016/j.oraloncology.2024.106760
|
| 13 |
Sonali Awasthi, Tejulal Prasad Chaurasia, Narendra Verma, Satakshi Chaturvedi, Anuradha Kalani, Sudhir Kumar Awasthi, Pramod K. Yadav, Abhijeet Singh, Gyanendra Singh, Rajeev Mishra. Promoter methylation signature of SLC16A11 gene reavels poor prognosis in head and neck squamous cell carcinoma. Human Gene 2026; 47 doi: 10.1016/j.humgen.2025.201525
|
| 14 |
Abhilash Deo, Sapir Levin, Chen Buxbaum, Madeleine Benguigui, Bar Manobla, Galit Saar, Noam Bosak, Eyal Bergmann, Ayelet Eran, Anat Grinfeld, Michal Harel, Coren Lahav, Ziv Raviv, Sameh Daher, Alona Zer, Julia Helena Reuter, Claus Peter Heuβel, Petros Christopoulos, Keren Yizhak, Yuval Shaked. PD-1 Blockade–Induced DKK1 Expression by CD8+ T Cells Promotes Blood–Brain Barrier Permeabilization. Cancer Discovery 2026; 16(5) doi: 10.1158/2159-8290.CD-25-1222
|
| 15 |
Helene Hersvik Aarstad, Svein Erik Emblem Moe, Stein Lybak, Øystein Bruserud, Tor Henrik Anderson Tvedt, Hans Jørgen Aarstad. Plasma IL-1 and IL-6 Family Cytokines with Soluble Receptor Levels at Diagnosis in Head and Neck Squamous Cell Carcinoma: High Levels Predict Decreased Five-Year Disease-Specific and Overall Survival. Cancers 2024; 16(8) doi: 10.3390/cancers16081484
|
| 16 |
Jiaqi Han, Ni Zeng, Kun Tian, Zijian Liu, Longjiang She, Zhu Wang, Jinlan He, Nianyong Chen. First‐line immunotherapy combinations for recurrent or metastatic nasopharyngeal carcinoma: An updated network meta‐analysis and cost‐effectiveness analysis. Head & Neck 2023; 45(9) doi: 10.1002/hed.27452
|
| 17 |
Wei Hu, Qingting Huang, Li Chen, Shikai Geng, Haojiong Zhang, Huaiyuan Chen, Xingyu Liu, Jingqin Zhong, Fengtao Su, Chunlin Shao, Lin Kong. Inhibition of DDR1 potentiates carbon ion radiotherapy by promoting ferroptosis and immunogenic death in head and neck squamous cell carcinoma. Journal of Translational Medicine 2025; 23(1) doi: 10.1186/s12967-025-07062-5
|
| 18 |
Ricardo D. Coletta, Ahmed Al-Samadi, W. Andrew Yeudall, Tuula Salo. Revisiting the grand challenges in oral cancers: advances in biomarkers and treatment strategies. Frontiers in Oral Health 2026; 7 doi: 10.3389/froh.2026.1875636
|
| 19 |
Jieqi Wang, Zhe Zhang, Yujia Wang, Bowen Li, Meihua Zheng, Jinsong Li. Dissecting the causal pathway linking HbA1c to oral cavity cancer via immune cell modulation: a bidirectional mendelian randomization analysis. Frontiers in Oncology 2026; 16 doi: 10.3389/fonc.2026.1768761
|
| 20 |
Daniel A. Ruiz-Torres, Saskia Naegele, Archana Podury, Lori Wirth, Sophia Z. Shalhout, Daniel L. Faden. Immunotherapy time of infusion impacts survival in head and neck cancer: A propensity score matched analysis. Oral Oncology 2024; 151 doi: 10.1016/j.oraloncology.2024.106761
|
| 21 |
Chenyi Zhao. Radiotherapy as an immunomodulator in cancer: Synergy with immunotherapy and roadmap for optimization. Journal of Radiation Research and Applied Sciences 2026; 19(1) doi: 10.1016/j.jrras.2026.102253
|
| 22 |
Maximilian Rink, Ernst-Michael Jung, Julian Künzel. The Use of Contrast-Enhanced Sonography for Therapy Monitoring of Metastatic Lymph Nodes: A Systematic Review. Current Oncology 2023; 30(7) doi: 10.3390/curroncol30070494
|
| 23 |
Katarzyna Starska-Kowarska. The Role of Different Immunocompetent Cell Populations in the Pathogenesis of Head and Neck Cancer—Regulatory Mechanisms of Pro- and Anti-Cancer Activity and Their Impact on Immunotherapy. Cancers 2023; 15(6) doi: 10.3390/cancers15061642
|
| 24 |
Ze Zhang, Kartik Sehgal, Keisuke Shirai, Rondi A. Butler, John K. Wiencke, Devin C. Koestler, Geat Ramush, Min Kyung Lee, Annette M. Molinaro, Hannah G. Stolrow, Ariel Birnbaum, Lucas A. Salas, Robert I. Haddad, Karl T. Kelsey, Brock C. Christensen. Methylation cytometric pretreatment blood immune profiles with tumor mutation burden as prognostic indicators for survival outcomes in head and neck cancer patients on anti-PD-1 therapy. npj Precision Oncology 2024; 8(1) doi: 10.1038/s41698-024-00759-8
|
| 25 |
Lifei Feng, Gaofei Yin, Wen Gao, Jugao Fang, Qi Zhong, Zhigang Huang, Wei Guo, Yang Zhang. Differentiation grade and combined positive score correlation in head and neck squamous cell carcinoma. World Journal of Surgical Oncology 2026; 24(1) doi: 10.1186/s12957-026-04231-8
|
| 26 |
Dong Hyun Kim, Mingu Kang, Gahee Park, Mohammad Mostafavi, Yoojoo Lim, Chan-Young Ock, Jiwon Koh, Yoon Kyung Jeon, Kyeong Cheon Jung, Soon-Hyun Ahn, Eun-Jae Chung, Seong-Keun Kwon, Bhumsuk Keam. Changes in the tumor microenvironment in recurrent head and neck squamous cell carcinoma and its implication on efficacy of immune checkpoint inhibitors. Discover Oncology 2024; 15(1) doi: 10.1007/s12672-024-01504-0
|
| 27 |
Matthaeus Stoehr, Johannes Stoehr, Andreas Dietz, Jan Gaebel. Reevaluation of the Bayesian network model to support immunotherapy decision-making in recurrent/metastatic head and neck squamous cell carcinoma. International Journal of Computer Assisted Radiology and Surgery 2026; doi: 10.1007/s11548-026-03803-z
|
| 28 |
Ruby Dwivedi, Ayushi Jain, Shalini Gupta, Shaleen Chandra. Immunotherapy: The Fourth Domain in Oral Cancer Therapeutics. Indian Journal of Otolaryngology and Head & Neck Surgery 2024; 76(3) doi: 10.1007/s12070-024-04565-3
|
| 29 |
Bolin Song, Ipsa Yadav, Jillian C. Tsai, Anant Madabhushi, Benjamin H. Kann. Artificial Intelligence for Head and Neck Squamous Cell Carcinoma: From Diagnosis to Treatment. American Society of Clinical Oncology Educational Book 2025; 45(3) doi: 10.1200/EDBK-25-472464
|
| 30 |
Alexis M. Sanwick, Ivis F. Chaple. Targeted radionuclide therapy for head and neck squamous cell carcinoma: a review. Frontiers in Oncology 2024; 14 doi: 10.3389/fonc.2024.1445191
|
| 31 |
Nidhi Anand, Pallavi Srivastava, Nuzhat Husain, Deeksha Agarwal, Anurag Gupta, Roma Pradhan. Evaluation of CTLA-4 and PD-L1 Expression in Thyroid Carcinoma and Its Prognostic Significance. Cureus 2024; doi: 10.7759/cureus.67004
|
| 32 |
Prabhat Kumar, Archita Dey, Rishabh Lakhera, Jayant Maini, Bhudev C. Das, Shilpi Gupta. Targeting transcriptional and post-transcriptional pathways in head and neck cancer. Biochimica et Biophysica Acta (BBA) - Reviews on Cancer 2026; 1881(4) doi: 10.1016/j.bbcan.2026.189647
|
| 33 |
Chen Li, Qi Cai, Jingwen Cai, Xuanyi Ma, Zhizen Quan, Yu Chen, Wenhao Tao, Xu Han, Yibo Wei, Xiaogang Xu. Integrated Single‐Cell and Spatial Multi‐Omics Reveal S100A12+ Neutrophil Reprogramming Across Oral Inflammatory States and Immunotherapy‐Associated Perturbation. BioFactors 2026; 52(5) doi: 10.1002/biof.70157
|
| 34 |
Kedar Kirtane, Maie St. John, Harry Fuentes-Bayne, Sandip P. Patel, Armen Mardiros, Han Xu, Eric W. Ng, William Y. Go, Deborah J. Wong, John B. Sunwoo, John S. Welch. Genomic Immune Evasion: Diagnostic and Therapeutic Opportunities in Head and Neck Squamous Cell Carcinomas. Journal of Clinical Medicine 2022; 11(24) doi: 10.3390/jcm11247259
|
| 35 |
Anna Schäfer, Lilli Zülch, Leonie Steinsdörfer, Anna-Jasmina Donaubauer, Clara Reichardt, Benjamin Frey, Rainer Fietkau, Marlen Haderlein, Stefanie Corradini, Udo S. Gaipl, Tina Jost. ATR inhibition in combination with hypofractionated radiotherapy is superior to ATM inhibition with regard to ex vivo CD8 + T cell activation particularly for HPV-negative head and neck cancer cells. Oral Oncology 2026; 179 doi: 10.1016/j.oraloncology.2026.108019
|
| 36 |
Geetpriya Kaur, Neetu Sinha, Nuno Vale, Rui Amaral Mendes. Targeted Therapies in Oral and Oropharyngeal Cancer: An Overview of Emerging and Repurposed Agents. Cancers 2025; 17(23) doi: 10.3390/cancers17233761
|
| 37 |
Dong Hyun Kim, Jong Seok Ahn, Mingu Kang, Gahee Park, Yoojoo Lim, Soohyun Hwang, Chan-Young Ock, Jiwon Koh, Eun-Jae Chung, Seong-Keun Kwon, Yoon Kyung Jeon, Kyeong Cheon Jung, Soon-Hyun Ahn, Bhumsuk Keam. Comparison of Tumor Microenvironments between Primary Tumors and Lymph Node Metastases in Head and Neck Squamous Cell Carcinoma and Their Predictive Role in Immune Checkpoint Inhibitor Treatment. Cells 2024; 13(18) doi: 10.3390/cells13181557
|
| 38 |
Juan Nicolás Aponte-Barreno, Esteban Ariel Cobo-Arroba, Jennifer Gabriela Lucio-Taboada, Yamily González-Cardona. Terapias dirigidas y desafíos odontológicos en el cáncer bucal: revisión sistemática. Cuaderno de odontología. Revista científica 2026; 4(especial5) doi: 10.62574/j5fm2902
|
| 39 |
Ming Yan, Li-yuan Xiao, Martin Gosau, Ralf Smeets, Hong-chao Feng, Simon Burg, Ling-ling Fu, Reinhard E. Friedrich. The role of herpes simplex virus infection in the etiology of head and neck cancer–a Mendelian randomization study. Frontiers in Immunology 2024; 15 doi: 10.3389/fimmu.2024.1278327
|
| 40 |
Md Tanjim Alam, Mishfak A. M. Mansoor, Sarah A. Ashiqueali, Pawel Golusinski, Ewelina Golusinska-Kardach, Joanna K. Strzelczyk, Blazej Rubis, Wojciech Golusinski, Michal M. Masternak. The Impact of Senescence-Associated Secretory Phenotype (SASP) on Head and Neck Cancers: From Biology to Therapy. Cancers 2025; 17(24) doi: 10.3390/cancers17244024
|
| 41 |
Cheyanne K. Shinn, Robert Saddawi-Konefka, Catherina L. Salanga, Shiruyeh Schokrpur, J. Silvio Gutkind, Tracy M. Handel. Exploiting the CXCR3/CXCL10 axis overrides tumor immune suppression by enhancing immune trafficking and effector cell priming in HNSCC. Proceedings of the National Academy of Sciences 2026; 123(34) doi: 10.1073/pnas.2522360123
|
| 42 |
Michail Athanasopoulos, Pinelopi Samara, Georgios Agrogiannis, Ioannis Athanasopoulos, Nikolaos Kavantzas, Efthymios Kyrodimos, Nicholas S. Mastronikolis. Releasing the brakes: the role of immune checkpoint inhibitors in laryngeal cancer. Exploration of Targeted Anti-tumor Therapy 2025; 6 doi: 10.37349/etat.2025.1002292
|
| 43 |
Abdula Monther, Riyam Al-Msari, Robert Saddawi-Konefka, Santiago Fassardi, Cynthia Tang, Chad Philips, Prakriti Sen, Pardis Mohammadzadeh, Kelsey Decker, Sayuri Miyauchi, Souvick Roy, Riley Jones, Xingyu Wu, Silvio Gutkind, Andrew Sharabi, Joseph Califano, Amirreza Khalaji. CD47 blockade (ALX301) enhances immunoradiotherapy response in HPV negative head and neck squamous cell carcinoma. PLOS One 2026; 21(2) doi: 10.1371/journal.pone.0328031
|